Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer

Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases develop resistance to radioactive iodine therapy due to tumor dedifferentiation. For DTC patients harboring BRAF(V600E) mutation, Vemurafenib, a BRAF kinase inhibitor, has dra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wei-Jun, Sun, Zhen-Kui, Shen, Chen-Tian, Song, Hong-Jun, Zhang, Xin-Yun, Qiu, Zhong-Ling, Luo, Quan-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381260/
https://www.ncbi.nlm.nih.gov/pubmed/28382170
http://dx.doi.org/10.7150/thno.17322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381260/
https://www.ncbi.nlm.nih.gov/pubmed/28382170
http://dx.doi.org/10.7150/thno.17322

Ejemplares similares